A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER 3

被引：0

作者：

Griffiths, Christopher E. ^{[1
]}

Reich, Kristian ^{[2
]}

Lebwohl, Mark ^{[3
]}

Van de Kerkhof, Peter ^{[4
]}

Paul, Carle ^{[5
]}

Menter, Alan ^{[6
]}

Carlier, Hilde ^{[7
]}

Cameron, Gregory ^{[7
]}

Erickson, Janelle ^{[7
]}

Zhang, Lu ^{[7
]}

Secrest, Roberta ^{[7
]}

Ball, Susan ^{[7
]}

Braun, Daniel ^{[7
]}

Osuntokun, Olawale ^{[7
]}

Heffernan, Michael ^{[7
]}

Nickoloff, Brian ^{[7
]}

Papp, Kim ^{[8
]}

机构：

[1] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England

[2] Dermatologickum Hamburg, Hamburg, Germany

[3] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA

[4] Radboud Univ Nijmegen, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands

[5] Univ Toulouse 3, Dept Dermatol, F-31062 Toulouse, France

[6] Univ Texas SW Med Ctr Dallas, SW Med Sch, Dallas, TX 75390 USA

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Prob Med Res, Waterloo, ON, Canada

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P059

引用

页码：S17 / S17

页数：1

共 50 条

[31] Efficacy of Ixekizumab in Patients with and without Previous Experience with Biologic Therapies Compared to Etanercept and Placebo: Results from UNCOVER-2, a Phase 3 Trial in Patients with Plaque Psoriasis
Lacour, J. -P.
Leutz, A.
Dutronc, Y.
Zhang, L.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
[32] Impact of ixekizumab treatment on scalp psoriasis: results from the placebo-controlled induction period of UNCOVER-3
Reich, K.
Leonardi, C.
Lebwohl, M.
Romiti, R.
Goldblum, O.
Zhang, L.
Shrom, D.
Dennehy, E.
Sofen, H.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 73
[33] Efficacy of ixekizumab in patients with and without previous experience with biologic therapies compared to etanercept and placebo: results from UNCOVER-2, a phase 3 trial in patients with plaque psoriasis
Lacour, Jean-Philippe
Dutronc, Yves
Zhang, Lu
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
[34] Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
Imafuku, Shinichi
Torisu-Itakura, Hitoe
Nishikawa, Atsushi
Zhao, Fangyi
Cameron, Gregory S.
[J]. JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1285 - 1290
[35] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Reich, Kristian
Leonardi, Craig
Lebwohl, Mark
Kerdel, Francisco
Okubo, Yukari
Romiti, Ricardo
Goldblum, Orin
Dennehy, Ellen B.
Kerr, Lisa
Sofen, Howard
[J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
[36] Improvement in nail psoriasis in the open-label extension period of a phase 2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
Rich, P.
Langley, R. G.
Menter, A.
Krueger, G. G.
Zhu, B.
Wei, H.
Cameron, G. S.
Heffernan, M. P.
Holzkaemper, T.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 135 - 136
[37] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Andrew Blauvelt
Kim A. Papp
Christopher E. M. Griffiths
Luis Puig
Jamie Weisman
Yves Dutronc
Lisa Farmer Kerr
Dapo Ilo
Lotus Mallbris
Matthias Augustin
[J]. American Journal of Clinical Dermatology, 2017, 18 : 273 - 280
[38] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
Warren, R. B.
Cather, J.
Ohtsuki, M.
Bleakman, A. Potts
Burge, R.
Zhu, B.
Reich, K.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
[39] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
Armstrong, April W.
Lynde, Charles W.
McBride, Sandy R.
Stahle, Mona
Edson-Heredia, Emily
Zhu, Baojin
Amato, David
Nikai, Enkeleida
Yang, Fan Emily
Gordon, Kenneth B.
[J]. JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
[40] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Sub-analysis of the Phase 3 UNCOVER trials in patients with baseline PASI > 15
Spelman, L.
Rubel, D.
Brnabic, A.
Burkhardt, N.
Kelin, K.
Gurbuz, S.
Foley, P.
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 40 - 41

← 1 2 3 4 5 →